Table 6.
Patients without post-operative treatment (n = 475, 80 with PCSM10)
| Model | OR (95% CI) | p value | AUC of model (95% CI) | Increase in AUC from adding GC |
|---|---|---|---|---|
| GC (per 0.1 unit) | 1.36 (1.22, 1.53) | <0.001 | 0.68 (0.61, 0.75) | (NA) |
| CAPRA-S (per 1 unit) | 1.42 (1.26, 1.59) | <0.001 | 0.71 (0.66, 0.77) | (NA) |
| Base model | (NA)a | <0.001 | 0.76 (0.70, 0.82) | (NA) |
| GC (per 0.1 unit), adjusted for base model | 1.20 (1.06, 1.37) | 0.005 | 0.78 (0.72, 0.83) | (0.02) |
| GC (per 0.1 unit), adjusted for CAPRA-S | 1.26 (1.12, 1.43) | <0.001 | 0.74 (0.68, 0.80) | (0.03) |
| GC (> 0.6 vs ≤ 0.6) | 4.48 (2.67, 7.52) | <0.001 | 0.58 (0.59, 0.71) | (NA) |
| GC (> 0.6 vs ≤ 0.6), adjusted for base model | 2.87 (1.62, 5.10) | <0.001 | 0.78 (0.73, 0.84) | (0.02) |
| GC (> 0.6 vs ≤ 0.6), adjusted for CAPRA-S | 3.29 (1.90, 5.67) | <0.001 | 0.74 (0.69, 0.80) | (0.03) |
AUC = area under the curve; CAPRA-S = Cancer of the Prostate Risk Assessment Postsurgical; CI = confidence interval; GC = Decipher genomic classifier; NA = not applicable; OR = odds ratio; PCSM = prostate cancer-specific mortality.
a
The base model includes preoperative prostate-specific antigen (continuous), prostatectomy Gleason score (7, 8, 9–10), prostatectomy stage (organ confined, extraprostatic extension, seminal vesicle involvement, lymph node metastasis). Because these are well established prognostic factors but are not the focus of this study, the individual odds ratios and 95% confidence intervals for these variables are not shown.